Lunch & Learn Webinar: “OTEZLA (apremilast) Label Update – Pediatric Psoriatic Arthritis & XR Formulation” and “LUMAKRAS® (sotorasib) Clinical Updates

Thursday, October 23 | 1:00 PM ET

The National Association of Specialty Pharmacy is pleased to announce a webinar presented by Amgen, titled “OTEZLA (apremilast) Label Update – Pediatric Psoriatic Arthritis & XR Formulation” and “LUMAKRAS® (sotorasib) Clinical Updates.” Join us to review the most recent Otezla label expansion, including the new indication for pediatric patients aged 6 years and older with Active Psoriatic Arthritis. We will also discuss the new Otezla XR 75mg tablet and its dosing considerations, and review the latest clinical updates and therapeutic advancements related to LUMAKRAS® in combination with Vectibix® for the treatment of adult patients with KRAS G12C–mutated metastatic colorectal cancer (mCRC).

Members may click here to login and register for this webinar.

Not a member? Join today!